[144] Protara Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Baker Brothers Life Sciences filed a Form 144 reporting proposed sales of Common Stock by broker. The filing lists proposed brokered transactions through Canaccord Genuity with a broker date of 03/04/2026. The record lists sales of 322,039 shares on 02/24/2026 and 947,479 shares on 02/25/2026. A line in the filing shows 53,587,260 shares with the date 03/04/2026 listed nearby.

Insights

Capital Markets Lawyer

Form 144 notifies the market of intended affiliate sales; this filing lists specific sale dates and broker involvement.

The filing records proposed brokered sales via Canaccord Genuity with a broker date of 03/04/2026 and disclosed sale quantities of 322,039 shares on 02/24/2026 and 947,479 shares on 02/25/2026. Form 144s are administrative notices required when affiliates effect sales under Rule 144.

Timing and final execution depend on the affiliate and broker; subsequent transaction confirmation will appear in trade records or Form 4/5 filings if required.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Canaccord Genuity LLC 99 High Street, Suite 1200 Boston MA 02110	424125	2654641.00	53587260	03/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/04/2026	See Remark 2	Broker			424125	03/04/2026	See Remark 2

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Baker Brothers Life Sciences, L.P. 860 Washington Street, 3rd Floor New York NY 10014	Common Stock	02/24/2026	322039	1944922.00
Baker Brothers Life Sciences, L.P. 860 Washington Street, 3rd Floor New York NY 10014	Common Stock	02/25/2026	947479	5501316.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)